Skip to main content

Liver Cancer


Guideline Updates
NCCN released an update to its guideline for hepatobiliary cancers, featuring updates in HCC, gallbladder cancer, intrahepatic cholangiocarcinoma, and biliary tract cancer.
True or False: Pembrolizumab is not considered a cost-effective second-line therapy for treating HCC.
Compared with selective internal radiotherapy, sorafenib is not unlikely cost-effective for HCC in the United States.
Study findings suggest pembrolizumab is not a cost-effective second-line therapy for HCC at its current price in the US.
Brian Seal, PhD, RPh, MBA discusses results from a study which examined the lines of loco-regional therapies received…
Back to Top